Takeda Pharmaceutical Company Limited Expense Of Restructuring Activities
Takeda Pharmaceutical Company Limited (TKPHF) reported Expense Of Restructuring Activities of JPY 123.58 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Cash Flow › Other Cash Flow Items
ifrs-full:ExpenseOfRestructuringActivities · last filed 2025-06-25
| Period end | Expense Of Restructuring Activities 12 month |
|---|---|
| 2025-03-31 | 123.58B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 73.83B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 56.91B JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | 83.36B JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | 104.48B JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | 130.37B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | 81.52B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | 30.13B JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | 51.17B JPY 20-F · filed 2019-06-27 |